$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224023481 Filed on June 11, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$89.10K	$35.00K	$31.30K
YoY Change	38.14%	11.82%	95.63%
Cost Of Revenue	$6.490K
YoY Change
Gross Profit	$82.61K
YoY Change	28.08%
Gross Profit Margin	92.72%
Selling, General & Admin	$1.259M	$3.086M	$4.299M
YoY Change	-43.1%	-28.22%	0.11%
% of Gross Profit	1524.32%
Research & Development	$1.292M	$1.058M	$1.511M
YoY Change	33.5%	-29.98%	94.91%
% of Gross Profit	1564.2%
Depreciation & Amortization	$47.71K	$42.71K	$39.35K
YoY Change	14.88%	8.54%	51.29%
% of Gross Profit	57.75%
Operating Expenses	$2.551M	$4.144M	$5.810M
YoY Change	-19.79%	-28.68%	14.61%
Operating Profit	-$2.469M	-$4.109M	-$5.779M
YoY Change	-20.78%	-28.89%	14.35%
Interest Expense	-$1.561M	$25.28K	$18.22K
YoY Change	-1722.48%	38.75%	-162.81%
% of Operating Profit
Other Income/Expense, Net	-$1.560M	$1.886M	$94.88K
YoY Change	-1246.89%	1887.85%	469.83%
Pretax Income	-$4.029M	-$2.223M	-$5.684M
YoY Change	35.16%	-60.89%	18.02%
Income Tax
% Of Pretax Income
Net Earnings	-$4.029M	-$2.200M	-$5.700M
YoY Change	35.16%	-61.4%	18.35%
Net Earnings / Revenue	-4521.39%	-6285.71%	-18210.86%
Basic Earnings Per Share	-$0.50	-$0.33	-$1.53
Diluted Earnings Per Share	-$0.50	-$0.33	-$1.53
COMMON SHARES
Basic Shares Outstanding	6.770M shares	6.770M shares	3.768M shares
Diluted Shares Outstanding	8.121M shares	6.671M shares	3.717M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.68M	$16.42M	$12.37M
YoY Change	26.39%	32.68%	-35.96%
Cash & Equivalents	$2.252M	$1.157M	$1.836M
Short-Term Investments	$12.43M	$15.26M	$10.54M
Other Short-Term Assets	$295.9K	$317.0K	$393.1K
YoY Change	-26.69%	-19.36%	-27.25%
Inventory
Prepaid Expenses
Receivables	$27.40K	$35.00K	$16.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$15.00M	$16.77M	$12.78M
YoY Change	24.58%	31.19%	-35.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$345.8K	$365.0K	$304.1K
YoY Change	10.11%	20.03%	-35.16%
Goodwill
YoY Change
Intangibles	$668.8K	$691.3K	$781.0K
YoY Change	-11.83%	-11.49%
Long-Term Investments
YoY Change
Other Assets	$22.38K	$9.540K
YoY Change
Total Long-Term Assets	$1.115M	$1.181M	$1.298M
YoY Change	-11.24%	-8.99%	24.78%
TOTAL ASSETS
Total Short-Term Assets	$15.00M	$16.77M	$12.78M
Total Long-Term Assets	$1.115M	$1.181M	$1.298M
Total Assets	$16.12M	$17.95M	$14.08M
YoY Change	21.19%	27.49%	-32.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$215.9K	$230.9K	$92.59K
YoY Change	-21.78%	149.39%	-56.71%
Accrued Expenses	$447.6K	$338.3K	$233.0K
YoY Change	15.87%	45.22%	-16.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$5.320M	$3.448M	$470.4K
YoY Change	554.46%	633.04%	-4.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$123.5K
YoY Change			-53.96%
Total Long-Term Liabilities	$0.00	$0.00	$123.5K
YoY Change	-100.0%	-100.0%	-53.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.320M	$3.448M	$470.4K
Total Long-Term Liabilities	$0.00	$0.00	$123.5K
Total Liabilities	$5.320M	$3.448M	$593.9K
YoY Change	493.44%	480.57%	-22.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$153.0M	-$148.9M	-$158.3M
YoY Change	-5.18%	-5.94%
Common Stock	$692.00	$677.00	$378.00
YoY Change	73.43%	79.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.80M	$14.50M	$13.49M
YoY Change
Total Liabilities & Shareholders Equity	$16.12M	$17.95M	$14.08M
YoY Change	21.19%	27.49%	-32.69%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$4.029M	-$2.200M	-$5.700M
YoY Change	35.16%	-61.4%	18.35%
Depreciation, Depletion And Amortization	$47.71K	$42.71K	$39.35K
YoY Change	14.88%	8.54%	51.29%
Cash From Operating Activities	-$1.865M	-$2.300M	-$2.300M
YoY Change	65.01%	0.0%	44.23%
INVESTING ACTIVITIES
Capital Expenditures	$35.30K		$60.02K
YoY Change	21.51%		-154.78%
Acquisitions
YoY Change
Other Investing Activities	$3.008M	-$4.928M	$2.569M
YoY Change	332.97%	-291.85%
Cash From Investing Activities	$2.973M	-$4.928M	$2.509M
YoY Change	346.56%	-296.44%	-2389.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-12.84K	$7.518M
YoY Change	-103.12%
NET CHANGE
Cash From Operating Activities	-1.865M	-$2.300M	-$2.300M
Cash From Investing Activities	2.973M	-$4.928M	$2.509M
Cash From Financing Activities	-12.84K	$7.518M
Net Change In Cash	1.095M	$272.7K	$159.9K
YoY Change	-2173.01%	70.55%
FREE CASH FLOW
Cash From Operating Activities	-$1.865M	-$2.300M	-$2.300M
Capital Expenditures	$35.30K		$60.02K
Free Cash Flow	-$1.900M	-$2.300M	-$2.360M
YoY Change	63.92%	-2.54%	58.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants		usd
CY2023Q1	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants		usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2023Q1	BRTX	Payments For Proceeds From Deferred Offering Costs PaymentsForProceedsFromDeferredOfferingCosts		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	BRTX	Accrued Purchases Of Equipment AccruedPurchasesOfEquipment		usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure		usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure		usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18216	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	149021	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	76660	usd
CY2024Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-137319	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1488350	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1885997	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1393474	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2223255	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7172572	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6671382	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6671382	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3717472	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3717472	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4742243	usd
CY2024Q1	BRTX	Stock Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	-48410	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	985038	usd
CY2024Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1043336	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2223255	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	14503327	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10290339	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10290339	usd
CY2023Q1	BRTX	Stock Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	-39308	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1188067	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2190428	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7172572	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6456954	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6456954	usd
CY2024Q1	BRTX	Aggregate Fair Value Of Common Stock AggregateFairValueOfCommonStock	3351580	shares
CY2024Q1	BRTX	Shares Held In Abeyance SharesHeldInAbeyance	1351580	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2223255	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7172572	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42713	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6769919	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6769919	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4706917	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4706917	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	677	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	471	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	163411257	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156689256	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148922589	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146699334	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	14503327	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10004375	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17951466	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12611720	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31300	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1058131	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1231745	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3086121	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4578653	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	4144252	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	5810398	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4109252	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5779098	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	162597	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18216	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	149021	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	76660	usd
CY2024Q1	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants	1711698	usd
CY2024Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-137319	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1488350	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1885997	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2223255	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7172572	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6671382	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6671382	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3717472	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3717472	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10004375	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4742243	usd
CY2024Q1	BRTX	Stock Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	-48410	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	985038	usd
CY2024Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1043336	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2223255	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	14503327	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10290339	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10290339	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1188067	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2190428	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7172572	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6456954	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6456954	usd
CY2024Q1	BRTX	Aggregate Fair Value Of Common Stock AggregateFairValueOfCommonStock	3351580	shares
CY2024Q1	BRTX	Shares Held In Abeyance SharesHeldInAbeyance	1351580	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7172572	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42713	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	39351	usd
CY2024Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	151596	usd
CY2023Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	63940	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2028374	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3378495	usd
CY2024Q1	BRTX	Noncash Lease Expense NoncashLeaseExpense	36062	usd
CY2023Q1	BRTX	Noncash Lease Expense NoncashLeaseExpense	29011	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15700	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	60142	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	69281	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-38781	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-33288	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2317780	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2379277	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5800000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4066501	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	10728006	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1467310	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60022	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4928006	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2539169	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7528027	usd
CY2024Q1	BRTX	Payments For Proceeds From Deferred Offering Costs PaymentsForProceedsFromDeferredOfferingCosts	9538	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7518489	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	272703	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	159892	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	884377	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1676577	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	39351	usd
CY2024Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	151596	usd
CY2023Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	63940	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2028374	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3378495	usd
CY2024Q1	BRTX	Noncash Lease Expense NoncashLeaseExpense	36062	usd
CY2023Q1	BRTX	Noncash Lease Expense NoncashLeaseExpense	29011	usd
CY2024Q1	BRTX	Gain On Exchange Of Warrants GainOnExchangeOfWarrants	1711698	usd
CY2024Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	137319	usd
CY2023Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	1488350	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15700	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	60142	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	69281	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	41513	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-78316	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-402589	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	102913	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-38781	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-33288	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2317780	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2379277	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5800000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4066501	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	10728006	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1467310	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60022	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4928006	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2539169	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7528027	usd
CY2024Q1	BRTX	Payments For Proceeds From Deferred Offering Costs PaymentsForProceedsFromDeferredOfferingCosts	9538	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7518489	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	272703	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	159892	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	884377	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1157080	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1836469	usd
CY2024Q1	BRTX	Accrued Purchases Of Equipment AccruedPurchasesOfEquipment	29246	usd
CY2024Q1	BRTX	Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	48410	usd
CY2023Q1	BRTX	Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	39308	usd
CY2024Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	8123391	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	595364	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2200000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2300000	usd
CY2024Q1	BRTX	Working Capital WorkingCapital	13300000	usd
CY2024Q1	BRTX	Proceeds From Warrant Exercises Gross ProceedsFromWarrantExercisesGross	7500000	usd
CY2024Q1	BRTX	Proceeds From Warrant Exercises Gross ProceedsFromWarrantExercisesGross	7500000	usd
CY2023Q4	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	73686	usd
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	338343	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	711686	usd
CY2024Q1	BRTX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingIntrinsicValue	0	usd
CY2024Q1	BRTX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1157080	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1836469	usd
CY2024Q1	BRTX	Accrued Purchases Of Equipment AccruedPurchasesOfEquipment	29246	usd
CY2024Q1	BRTX	Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	48410	usd
CY2023Q1	BRTX	Return And Cancellation Of Shares In Lieu Of Payroll Tax Withholding ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding	39308	usd
CY2024Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	8123391	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	595364	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2200000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2300000	usd
CY2024Q1	BRTX	Working Capital WorkingCapital	13300000	usd
CY2024Q1	BRTX	Proceeds From Warrant Exercises Gross ProceedsFromWarrantExercisesGross	7500000	usd
CY2024Q1	BRTX	Proceeds From Warrant Exercises Gross ProceedsFromWarrantExercisesGross	7500000	usd
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zgGDRd97r4ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zvXSM0EqWwo2">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period statements of operations, changes in stockholders’ equity and cash flows amounts have been reclassified to conform to the Company’s fiscal 2024 presentation. These reclassifications have no impact on the Company’s previously reported net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zrorIQwSvQBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zxYUGvrWvXkg">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation (“FDIC”) coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zL31Lk7yyYfc" title="FDIC insured limit">250,000</span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_c20240331_z7B5xD37PMi2" title="FDIC amount">830,125</span> and $<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zmtmG0caAtfi" title="FDIC amount">604,226</span> as of March 31, 2024 and December 31, 2023, respectively. As of March 31, 2024, the Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The royalties related to the Company’s sublicense comprised all of the Company’s revenue during the three months ended March 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	830125	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	604226	usd
CY2024Q1	BRTX	Shares Held In Abeyance SharesHeldInAbeyance	1351580	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8752606	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7900716	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1934716	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.45
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3401608	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.60
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2028811	shares
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zrorIQwSvQBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zxYUGvrWvXkg">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation (“FDIC”) coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zL31Lk7yyYfc" title="FDIC insured limit">250,000</span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_c20240331_z7B5xD37PMi2" title="FDIC amount">830,125</span> and $<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zmtmG0caAtfi" title="FDIC amount">604,226</span> as of March 31, 2024 and December 31, 2023, respectively. As of March 31, 2024, the Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The royalties related to the Company’s sublicense comprised all of the Company’s revenue during the three months ended March 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	830125	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	604226	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8752606	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7900716	shares
CY2024Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	143594	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	638000	usd
CY2024Q1	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	194749	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	143594	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	638000	usd
CY2024Q1	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	194749	usd
CY2023Q4	BRTX	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	73686	usd
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	338343	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	711686	usd
CY2024Q1	BRTX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingIntrinsicValue	0	usd
CY2024Q1	BRTX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1466892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.11
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1466892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.11
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1934716	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.45
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3401608	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.60
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2028811	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.22
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2028374	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3378495	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	115385	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	212749	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123536	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	144821	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	123536	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.22
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	42007	usd
CY2024Q1	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	38781	usd
CY2023Q1	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	33288	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2028374	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3378495	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2028374	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3378495	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	43265	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	42007	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	43265	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	42007	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	43265	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2028374	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3378495	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	43265	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	42007	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	43265	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	42007	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	43265	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	42007	usd
CY2024Q1	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	38781	usd
CY2023Q1	BRTX	Operating Lease Liability Reduction OperatingLeaseLiabilityReduction	33288	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	115385	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	212749	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123536	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	144821	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	129795	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	129795	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6259	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	123536	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	2189420	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	129795	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	129795	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6259	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	123536	usd
CY2024Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	2189420	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2189420	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1115334	usd
CY2024Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	137319	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2755358	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	15261220	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15261220	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	10181618	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10181618	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2755358	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1543953	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1543953	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2189420	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1115334	usd
CY2024Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	137319	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2755358	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	15261220	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15261220	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	10181618	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10181618	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2755358	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1543953	usd

Files In Submission

Name	View Source	Status
0001493152-24-023481-index-headers.html	Edgar Link	pending
0001493152-24-023481-index.html	Edgar Link	pending
0001493152-24-023481.txt	Edgar Link	pending
0001493152-24-023481-xbrl.zip	Edgar Link	pending
brtx-20240331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
brtx-20240331_cal.xml	Edgar Link	unprocessable
brtx-20240331_lab.xml	Edgar Link	unprocessable
brtx-20240331_def.xml	Edgar Link	unprocessable
brtx-20240331_pre.xml	Edgar Link	unprocessable
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2024 Q2 Form 10-Q Financial Statement

#000149315224023481 Filed on June 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2024 Q2 Form 10-Q Financial Statement

#000149315224023481 Filed on June 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx